Except for DNMT3A and PTPRD co-mutations, the response to treatment and favorable survival outcomes of this small NPM1-mutated MDS patient cohort, were not negatively influenced by co-mutations in IDH2, NRAS and FLT3 genes, highlighting the importance of identifying molecular landscapes, predictive of response to different therapeutic approaches [85]. This evidence concerns the gene FLT3 and myelodysplastic syndrome.